Abdera Therapeutics Inc.

Abdera Therapeutics Inc. , based in Vancouver, Canada, focuses on developing advanced cancer treatment solutions utilizing its proprietary ROVEr™ platform for creating innovative radiopharmaceuticals. Founded in 2020 in Vancouver, Canada, Abdera Therapeutics Inc. is dedicated to advancing cancer therapies through its research and development efforts.

The company has engaged in three deals, with its most recent funding round occurring on April 20, 2023. The firm raised CAD 8. 00 mn during the Seed round, which constitutes the total amount raised to date. The company was co-founded by Lana Janes and Mike Abrams, and its current CEO is Lori Lyons-Williams.

Abdera Therapeutics specializes in advanced cancer treatment solutions through its proprietary ROVEr™ platform, which integrates antibody engineering and radiotherapeutics to develop novel radiopharmaceuticals. The primary focus of this platform is on constructing targeted therapies that deliver radionuclide payloads, either alpha or beta-emitting, to a wide array of solid tumor targets, enhancing therapeutic effects while minimizing systemic toxicities. The company’s lead product, ABD-147, is currently undergoing a Phase 1 clinical trial for small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Targeted primarily at oncological healthcare providers, research institutions, and clinical trial participants, Abdera aims to address critical unmet needs in cancer treatment.

Geographically, Abdera’s products are positioned in markets that include North America and Europe, where advanced cancer therapies are in high demand. Revenue generation for Abdera Therapeutics is driven by its clinical development programs, specifically through partnerships with healthcare institutions and pharmaceutical companies involved in cancer treatment. Transactions occur primarily in a B2B context, where Abdera collaborates with clinical research organizations and healthcare providers to facilitate the development and potential commercialization of its radiotherapeutics. These collaborations often involve upfront payments for access to proprietary technology, milestone payments as products advance through clinical trials, and royalties on future sales of successful therapies.

The company’s flagship product, ABD-147, represents a cornerstone of its revenue potential as it moves through critical testing phases aimed at securing regulatory approval. Following its recent funding round on April 20, 2023, where Abdera Therapeutics Inc. raised CAD 8. 00 mn, the company will utilize these funds to further develop its ROVEr™ platform and accelerate the testing of its new cancer medicines.

Abdera plans to expand its product offerings and target markets, particularly within North America and Europe, to meet the growing demand for advanced cancer therapies. The firm is focused on solidifying partnerships with healthcare providers and research institutions to enhance the reach and impact of its innovative treatment solutions.